Indications
Methylprednisolone is used in a number of conditions, grouped here by body system. Endocrine disorders: primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, nonsuppurative thyroiditis, and hypercalcemia associated with cancer. Rheumatic disorders: juvenile rheumatoid arthritis, ankylosing spondylitis, acute and subacute bursitis, synovitis of osteoarthritis, acute nonspecific tenosynovitis, post-traumatic osteoarthritis, psoriatic arthritis, epicondylitis and acute gouty arthritis. Collagen diseases: systemic lupus erythematosus, systemic dermatomyositis and acute rheumatic carditis. Dermatologic diseases: bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), severe seborrheic dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus and severe psoriasis. Allergy: seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, serum sickness, contact dermatitis, bronchial asthma and atopic dermatitis. Ophthalmic diseases: allergic corneal ulcers, herpes zoster ophthalmicus, anterior segment inflammation, sympathetic ophthalmia, keratitis, optic neuritis, allergic conjunctivitis, chorioretinitis, and iritis and iridocyclitis. Respiratory diseases: symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis and aspiration pneumonitis. Hematological disorders: idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia and congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of leukemias and lymphomas in adults, and acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal disease: to tide the patient over a critical period of the disease in ulcerative colitis and regional enteritis. CNS disease: acute exacerbations of multiple sclerosis.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Pharmacodynamic properties
Methylprednisolone is a potent anti-inflammatory agent and can strongly suppress the immune system. Glucocorticoids mainly bind to and activate glucocorticoid receptors inside the cell. Once activated, these receptors bind to the promoter regions of DMA (which may activate or suppress transcription) and activate transcription factors, and this leads to inactivation of genes through deacetylation of histones. Methylprednisolone influences the kidney, fluid and electrolyte balance, lipid, protein and carbohydrate metabolism, skeletal muscle, the cardiovascular system, the immune system, the nervous system and the endocrine system.
Pharmacokinetic properties
After oral administration in normal healthy adults, the absolute bioavailability of Methylprednisclone is generally high (82% to 89%). It is absorbed rapidly, and the maximum plasma concentration is reached around 1.5 to 2.3 hours across doses. The medicine is widely distributed into the tissues, with a volume of distribution of 41 to 61.5 liter. It crosses the Wood-brain barrier and the placental barrier, and it is secreted in breast milk. Plasma protein binding in humans is approximately 77%. The liver metabolises it to inactive metabolites. No dosing adjustments are necessary for renal failure. Methylprednisolone is haemodializable.
Pregnancy & Breastfeeding
Methylprednisolone is in pregnancy category C. Give it only if the possible benefit to the mother justifies the possible risk to the foetus. Methylprednisolone has not been properly studied in nursing mothers.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.